【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於有骨折風險、腎功能不佳 (CrCl<30mL/min)之老年人。

重鬱症、糖尿病週邊神經痛、廣泛性焦慮症 Major depressive disorder、Diabetic peripheral neuropathy – Pain、Generalized anxiety disorder

Duloxetine HCl, a selective serotonin and norepinephrine reuptake inhibitor, exerts its antidepressant and pain inhibitory actions by potentiating the serotonergic and noradrenergic activity in the CNS.

Absorption: well absorbed after oral administration, time to peak concentration: 6 to 10 hr; Protein binding: > 90%; Metabolism: Hepatic, via CYP1A2 and CYP2D6; elimination half-life about 12 hour; Excretion: As metabolites; urine (72%), feces (19%)

Hypersensitivity to duloxetine; Concomitant use or within 2 weeks of MAO inhibitors; uncontrolled narrow-angle glaucoma; hepatic impairment; severe renal impairment (Clcr <30 Ml/min) or end-stage renal disease (ESRD)

C

Enters breast milk/not recommended

Nausea, dry mouth, constipation, diarrhea, appetite decreased, dizziness, somnolence, headache, insomnia

Initial: 40-60 mg/day; dose may be divided, maintenance: 60 mg once daily; administered without regard to meals; Capsule should be swallowed whole; do not break open or crush. Doses >60 mg/day have not been demonstrated to be more effective. Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose for such treatment. Duloxetine is not FDA approved for use in children.